RVTY's strong product portfolio raises optimism about the stock.

QDEL's strong product portfolio raises optimism about the stock.

PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.

Veeva Systems' Site Connect is likely to aid the sponsors in reducing trial time and expense.

STE's strong prospects in the healthcare business arm bode well for investors.

Jack in the Box's emphasis on differentiated menu offerings and digital efforts bode well. However, elevated labor costs are concerns.